| Literature DB >> 27939881 |
Kathryn Van Hook1, Zhiping Wang1, Dexi Chen2, Casey Nold1, Zhiyi Zhu1, Pavana Anur3, Hun-Joo Lee1, Zhiyong Yu4, Brett Sheppard5, Mu-Shui Dai3, Rosalie Sears3, Paul Spellman3, Charles D Lopez6.
Abstract
ASPP2 is a tumor suppressor that works, at least in part, through enhancing p53-dependent apoptosis. We now describe a new ASPP2 isoform, ΔN-ASPP2, generated from an internal transcription start site that encodes an N-terminally truncated protein missing a predicted 254 amino acids. ΔN-ASPP2 suppresses p53 target gene transactivation, promoter occupancy, and endogenous p53 target gene expression in response to DNA damage. Moreover, ΔN-ASPP2 promotes progression through the cell cycle, as well as resistance to genotoxic stress-induced growth inhibition and apoptosis. Additionally, we found that ΔN-ASPP2 expression is increased in human breast tumors as compared to adjacent normal breast tissue; in contrast, ASPP2 is suppressed in the majority of these breast tumors. Together, our results provide insight into how this new ASPP2 isoform may play a role in regulating the ASPP2-p53 axis.Entities:
Keywords: ASPP2; Tumor suppressor; p53
Mesh:
Substances:
Year: 2016 PMID: 27939881 PMCID: PMC5237613 DOI: 10.1016/j.bbrc.2016.12.027
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575